Ciprofloxacin selects for RNA polymerase mutations with pleiotropic antibiotic resistance effects

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 1, 2017, Pages 75-84

  Pietsch, Franziska ^a   Bergman, Jessica M ^a   Brandis, Gerrit ^a   Marcusson, Linda L ^a   Zorzet, Anna ^a   Huseby, Douglas L ^a   Hughes, Diarmaid ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; KANAMYCIN; RIFAMPICIN; RNA POLYMERASE; TETRACYCLINE; ANTIINFECTIVE AGENT; DNA DIRECTED RNA POLYMERASE; RNA POLYMERASE BETA SUBUNIT;

ALLELE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CLONE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; MDTK GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PLEIOTROPY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; RPOB GENE; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; GENE EXPRESSION PROFILING; GENETIC SELECTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; MUTATION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; GENE EXPRESSION PROFILING; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; SELECTION, GENETIC; SEQUENCE ANALYSIS, RNA;

EID: 85014561417     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw364     Document Type: Article

References (42)

1. Castro W, Navarro M, Biot C. Medicinal potential of ciprofloxacin and its derivatives. Future Med Chem 2013; 5: 81-96.
2. Aidara-Kane A. Containment of antimicrobial resistance due to use of antimicrobial agents in animals intended for food: WHO perspective. Rev Sci Tech 2012; 31: 277-87.
3. Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011; 24: 545-53.
4. Chen YH, Ko WC, Hsueh PR. The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens. Eur J Clin Microbiol Infect Dis 2012; 31: 1699-704.
5. EUCAST. MIC Distributions and ECOFFs. http://www.eucast.org/mic_distributions_and_ecoffs/.
6. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem 2003; 3: 249-82.
7. Marcusson LL, Frimodt-Moller N, Hughes D. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 2009; 5: e1000541.
8. Nazir H, Cao S, Hasan F et al. Can phylogenetic type predict resistance development? J Antimicrob Chemother 2011; 66: 778-87.
9. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 6.0, 2016. http://www.eucast.org.
10. Fabrega A, Martin RG, Rosner JL et al. Constitutive SoxS expression in a fluoroquinolone-resistant strain with a truncated SoxR protein and identification of a new member of the marA-soxS-rob regulon, mdtG. Antimicrob Agents Chemother 2010; 54: 1218-25.
11. Blattner FR, Plunkett G III, Bloch CA et al. The complete genome sequence of Escherichia coli K-12. Science 1997; 277: 1453-74.
12. Ellis HM, Yu D, DiTizio T et al. High efficiency mutagenesis, repair, and engineering of chromosomal DNA using single-stranded oligonucleotides. Proc Natl Acad Sci USA 2001; 98: 6742-6.
13. Koskiniemi S, Pranting M, Gullberg E et al. Activation of cryptic aminoglycoside resistance in Salmonella enterica. Mol Microbiol 2011; 80: 1464-78.
14. Gullberg E, Cao S, Berg OG et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog 2011; 7: e1002158.
15. Reynolds MG. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 2000; 156: 1471-81.
16. Brandis G, Wrande M, Liljas L et al. Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol Microbiol 2012; 85: 142-51.
17. Brandis G, Hughes D. Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J Antimicrob Chemother 2013; 68: 2493-7.
18. Brandis G, Pietsch F, Alemayehu R et al. Comprehensive phenotypic characterization of rifampicin resistance mutations in Salmonella provides insight into the evolution of resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2015; 70: 680-5.
19. Aberg A, Fernandez-Vazquez J, Cabrer-Panes JD et al. Similar and divergent effects of ppGpp and DksA deficiencies on transcription in Escherichia coli. J Bacteriol 2009; 191: 3226-36.
20. Jin DJ, Turnbough CL Jr. An Escherichia coli RNA polymerase defective in transcription due to its overproduction of abortive initiation products. J Mol Biol 1994; 236: 72-80.
21. Ishihama A, Shimada T, Yamazaki Y. Transcription profile of Escherichia coli: genomic SELEX search for regulatory targets of transcription factors. Nucleic Acids Res 2016; 44: 2058-74.
22. Ince D, Hooper DC. Quinolone resistance due to reduced target enzyme expression. J Bacteriol 2003; 185: 6883-92.
23. Zhang DF, Jiang B, Xiang ZM et al. Functional characterisation of altered outer membrane proteins for tetracycline resistance in Escherichia coli. Int J Antimicrob Agents 2008; 32: 315-9.
24. Apirion D, Schlessinger D. Coresistance to neomycin and kanamycin by mutations in an Escherichia coli locus that affects ribosomes. J Bacteriol 1968; 96: 768-76.
25. Buckel P, Buchberger A, Bock A et al. Alteration of ribosomal protein L6 in mutants of Escherichia coli resistant to gentamicin. Mol Gen Genet 1977; 158: 47-54.
26. Swick MC, Morgan-Linnell SK, Carlson KM et al. Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance. Antimicrob Agents Chemother 2011; 55: 921-4.
27. Morita Y, Kodama K, Shiota S et al. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother 1998; 42: 1778-82.
28. Nishino K, Yamaguchi A. Analysis of a complete library of putative drug transporter genes in Escherichia coli. J Bacteriol 2001; 183: 5803-12.
29. Long F, Rouquette-Loughlin C, Shafer WM et al. Functional cloning and characterization of the multidrug efflux pumps NorM fromNeisseria gonorrhoeae and YdhE from Escherichia coli. Antimicrob Agents Chemother 2008; 52: 3052-60.
30. Trinh V, Langelier MF, Archambault J et al. Structural perspective on mutations affecting the function of multisubunit RNA polymerases. Microbiol Mol Biol Rev 2006; 70: 12-36.
31. Sato T, Yokota S, Uchida I et al. A fluoroquinolone-resistant Escherichia coli clinical isolate without quinolone resistance-determining region mutations found in Japan. Antimicrob Agents Chemother 2011; 55: 3964-5.
32. Sato T, Yokota SI, Uchida I et al. Fluoroquinolone resistance mechanisms in an Escherichia coli isolate, HUE1, without quinolone resistancedetermining region mutations. Front Microbiol 2013; 4: 125.
33. Sun YW, Dai MH, Hao HH et al. The role of RamA on the development of ciprofloxacin resistance in Salmonella enterica serovar Typhimurium. PLoS One 2011; 6: e23471.
34. Ricci V, Blair JMA, Piddock LJV. RamA, which controls expression of the MDR efflux pump AcrAB-TolC, is regulated by the Lon protease. J Antimicrob Chemother 2014; 69: 643-50.
35. Mirkin SM, Bogdanova ES, Gorlenko ZM et al. DNA supercoiling and transcription in Escherichia coli: influence of RNA polymerase mutations. Mol Gen Genet 1979; 177: 169-75.
36. Blanc-Potard AB, Gari E, Spirito F et al. RNA polymerase (rpoB) mutants selected for increased resistance to gyrase inhibitors in Salmonella typhimurium. Mol Gen Genet 1995; 247: 680-92.
37. Petty NK, Ben Zakour NL, Stanton-Cook M et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci USA 2014; 111: 5694-9.
38. Clark G, Paszkiewicz K, Hale J et al. Genomic analysis uncovers a phenotypically diverse but genetically homogeneous Escherichia coli ST131 clone circulating in unrelated urinary tract infections. J Antimicrob Chemother 2012; 67: 868-77.
39. Price LB, Johnson JR, Aziz M et al. The epidemic of extended-spectrumb-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. MBio 2013; 4: e00377-13.
40. Xia E, Khong WX, Marimuthu K et al. Draft genome sequence of a multidrug-resistant NewDelhi metallo-β-lactamase-1 (NDM-1)-producing Escherichia coli isolate obtained in Singapore. Genome Announc 2013; 1: e01020-13.
41. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-42.
42. WHO. Treatment of Tuberculosis: Guidelines. 4th edn. Geneva: WHO Press, 2010.